James Daniel Lord MD PhD
Advanced Endoscopic Interventional, Inflammatory Bowel Disease
Virginia Mason Medical Center
Join to View Full Profile
1959 NE Pacific St# C212Seattle, WA 98195
Phone+1 206-543-0065
Fax+1 206-625-7195
Dr. Lord is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Gastroenterology, 2004 - 2008- University of WashingtonResidency, Internal Medicine, 2001 - 2004
- University of Washington School of MedicineClass of 2001
Certifications & Licensure
ID State Medical License 2002 - Present
WA State Medical License 2003 - 2026
American Board of Internal Medicine Gastroenterology
Publications & Presentations
PubMed
- Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.Elisa K Boden, Ramya Kongala, Duncan C Hindmarch, Donna M Shows, Julius G Juarez
Inflammatory Bowel Diseases. 2024-05-02 - 4 citationsJanus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.Duncan C Hindmarch, Sofya Malashanka, Donna M Shows, Astrid S Clarke, James D Lord
Journal of Crohn's & Colitis. 2024-04-23 - 3 citationsRegulatory T cells use heparanase to access IL-2 bound to extracellular matrix in inflamed tissue.Hunter A Martinez, Ievgen Koliesnik, Gernot Kaber, Jacqueline K Reid, Nadine Nagy
Nature Communications. 2024-02-20
Grant Support
- Characterizing circulating and visceral T cells specific for the autoantigen integrin αvβ6 in ulcerative colitisBENAROYA RESEARCH INST AT VIRGINIA MASON2024–2026
- Characterizing circulating and visceral T cells specific for the autoantigen integrin αvβ6 in ulcerative colitisBENAROYA RESEARCH INST AT VIRGINIA MASON2024–2026
- DCs as clinical targets of anti-integrin therapy in IBDBENAROYA RESEARCH INST AT VIRGINIA MASON2023–2025
- Intestinal Dendritic Cell Modulation Of Regulatory T Cell Function In IBDNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
- Intestinal Dendritic Cell Modulation Of Regulatory T Cell Function In IBDNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2009
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
